Latest news with #T1DM
India Today
28-05-2025
- Health
- India Today
From diagnosis to daily care: What every parent should know about juvenile diabetes
Juvenile diabetes, or Type 1 diabetes mellitus (T1DM), is an autoimmune condition where the pancreas produces little to no insulin. Unlike Type 2 diabetes, T1DM is not linked to lifestyle factors and often manifests in children and adolescents. In India, the prevalence of T1DM among children is rising, yet awareness and resources remain GROWING BURDEN IN INDIA India has the highest number of children and adolescents living with T1DM globally. According to the International Diabetes Federation (IDF) Diabetes Atlas 2021, approximately 1.2 million individuals aged 0-19 years are affected worldwide, with India contributing a significant portion. Studies indicate a higher prevalence in urban areas compared to rural regions. For instance, in Karnal, Haryana, the prevalence is 26.6 per 100,000 in urban areas versus 4.27 per 100,000 in rural Mehta, 16, student from Mumbai"Living with Type 1 diabetes isn't about being perfect every day - it's about being prepared. I carry my insulin kit like I carry my phone - always with me, always charged. It's just part of life now."RECOGNISING THE SYMPTOMS Early detection is crucial. Common symptoms include: advertisement A study from B.J. Medical College, Ahmedabad, found that polyuria and polydipsia were present in 81.4% of pediatric T1DM cases."Type 1 diabetes, also called juvenile diabetes, is a disease in which the pancreas makeslittle or no insulin, a hormone that enables sugar to enter cells and be used for energy. Children orteenagers are the most often affected demographic. It is, however, not a resultof lifestyle and cannot be prevented, unlike Type 2 diabetes. Type1 diabetes is an autoimmune disease and is closely related to genetic susceptibility, but there may be environmental factors as well. There is no cure for it, but early diagnosis and lifelong insulin treatment, as well as a strict diet and regular monitoring,help control the disease and prevent complications."Dr. Ritesh Agarwal, Consultant - Endocrinologist, Manipal Hospital, BhubaneshwarMANAGEMENT AND TREATMENTManaging T1DM requires a comprehensive approach:Insulin Therapy: Multiple daily injections or insulin pumpsBlood Glucose Monitoring: Regular checks to maintain optimal levelsDietary Management: Balanced meals with controlled carbohydrate intakePhysical Activity: Regular exercise to improve insulin sensitivityThe Ahmedabad study highlighted that the basal-bolus insulin regimen achieved better glycemic control with fewer hypoglycemic events compared to the split-mix Renu Khanna, Pediatric Endocrinologist "Type 1 diabetes in children is not a lifestyle disease - it's an autoimmune condition that demands lifelong commitment. With the right support, education, and access to insulin, these kids can lead full, active lives just like any other child."CHALLENGES IN INDIAadvertisementDespite medical advancements, several challenges persist:Lack of Awareness: Many are unaware that children can develop Access to Care: Especially in rural areas, access to insulin, monitoring devices, and trained healthcare professionals is Constraints: The cost of lifelong insulin therapy and monitoring can be prohibitive for many Impact: Children may face stigma, leading to emotional and psychological Brij Makkar, President of the Research Society for the Study of Diabetes in India (RSSDI), said in a research report "With an estimated 8.6 lakh T1D patients in India, we cannot afford to overlook the urgent needs of children living with this JUVENILE DIABETES IN INDIA REQUIRES:Enhanced Awareness Campaigns: Educating the public about T1DM symptoms and Healthcare Infrastructure: Ensuring availability of insulin and monitoring tools across the Healthcare Professionals: Specialised training for the early diagnosis and management of paediatric Implementation: Integrating T1DM care into national health programs to provide structured supportBy prioritising these steps, India can improve outcomes for children with T1DM, ensuring they lead healthy and fulfilling Note: This article is for informational purposes and is not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis and Watch
Yahoo
22-04-2025
- Health
- Yahoo
Noster research: Gut Microbiome-Derived HYA Shows Promise for Managing Blood Sugar in Type 1 Diabetes
KYOTO, Japan, April 22, 2025 /PRNewswire/ -- A new study has found that 10-hydroxy-cis-12-octadecenoic acid (HYA), a metabolite derived from linoleic acid by gut microbiota, can help reduce postprandial hyperglycemia (high blood sugar after meals) in type 1 diabetes (T1DM) model rats. Conducted by researchers from Wakayama Medical University, Hokkaido University, and Noster Inc., this study provides new insights into how microbial metabolites can be leveraged to improve postprandial hyperglycemia. Background on HYA and Diabetes Management Diabetes, particularly T1DM, requires careful management of blood sugar levels to prevent complications such as cardiovascular disease, nerve damage, and vision impairment. While insulin therapy is the cornerstone of T1DM treatment, postprandial hyperglycemia remains a challenge, increasing the risk of long-term health issues. Previous research has shown that fatty acids can influence glucose metabolism through gut hormone signaling. Linoleic acid, a common dietary fat, has been found to activate G protein-coupled receptor 120 (GPR120), promoting the secretion of glucagon-like peptide-1 (GLP-1), which helps regulate blood glucose. However, linoleic acid is also linked to inflammatory responses, limiting its therapeutic potential. HYA, a lipid metabolite produced by Gut microbiome from linoleic acid, has emerged as a promising alternative. It retains the ability to activate GPR120 and stimulate gut hormone secretion but without triggering inflammation. Key Findings The study investigated whether oral administration of HYA before a glucose tolerance test (OGTT) could help regulate blood sugar levels in both normal and T1DM model rats. The researchers found that HYA: Amelioration of post-meal hyperglycemia: HYA slowed the rise in blood glucose levels in normal and diabetic rats, suggesting its potential for managing post-meal glucose spikes. Enhanced Gut Hormone Secretion: HYA increased levels of GLP-1 and cholecystokinin (CCK), hormones known to improve glucose metabolism through slow gastric emptying. Inhibited Glucose Absorption: HYA partially blocked glucose uptake by inhibiting the sodium-glucose transporter (SGLT1), further preventing sharp increases in blood sugar. Worked in Combination with Insulin: When combined with bolus insulin treatment in T1DM model rats, HYA further improved postprandial glucose control. Implications for Diabetes Treatment These findings highlight the potential of gut microbiome-derived metabolites in diabetes management. Unlike traditional treatments that focus solely on insulin secretion, HYA appears to work through multiple mechanisms—slowing gastric motility, enhancing gut hormone secretion, and inhibiting glucose absorption—without the risk of promoting inflammation. "Our study suggests that HYA could be a beneficial dietary supplement for controlling postprandial blood sugar levels, particularly in type 1 diabetes patients using insulin therapy," says Yuta Yamamoto, the study's lead author. With the increasing focus on gut microbiome-derived metabolites in health and disease management, HYA represents an exciting avenue for future research and potential therapeutic development. Reference Yamamoto, Y., Narumi, K., Yamagishi, N. et al. HYA ameliorated postprandial hyperglycemia in type 1 diabetes model rats with bolus insulin treatment. Acta Diabetologica (2025). Company Overview Name: Noster Kohey KitaoHead Office & Research Center: 35-3 Minamibiraki, Kamiueno-cho, Muko, Kyoto 617-0006, JapanBusiness: Research, development, and sales of biopharmaceuticals and functional foodsWebsite: Contact Information Public Relations: Nanami Akatsuka (Ms) Tel: +81-75-921-5303 / Fax: +81-75-924-2702Email: contact@ View original content: SOURCE Noster Inc Sign in to access your portfolio
